Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 08, 2014; 82 (10 Supplement) April 30, 2014

Baseline Performance on 6MWT Correlates with Other Functional Outcomes in a Phase IIb Study of Exon-Skipping Antisense Oligonucleotide Eteplirsen for Use in Duchenne Muscular Dystrophy (DMD) (P5.091)

Jihad Saoud, Jerry Mendell, Louise Rodino-Klapac, Zarife Sahenk, Kandice Roush, Loren Bird, Linda Lowes, Lindsay Alfano, Ana Maria Gomez Ramirez, Sarah Lewis, Vinod Malik, Kim Shontz, Christopher Shilling, Peter Sazani, Edward Kaye
First published April 9, 2014,
Jihad Saoud
7Sarepta Therapeutics Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerry Mendell
8The Research Institute at Nationwide Children's Hospital Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise Rodino-Klapac
4Nationwide Children's Hospital Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zarife Sahenk
9The Research Institute at Nationwide Childrens.org Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kandice Roush
1Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loren Bird
6Nationwide Children’s Hospital Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda Lowes
1Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsay Alfano
3National Children's Hospital Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Maria Gomez Ramirez
5Nationwide Childrens Hospital Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Lewis
1Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vinod Malik
5Nationwide Childrens Hospital Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim Shontz
1Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Shilling
2Columbus Children's Research Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Sazani
7Sarepta Therapeutics Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Kaye
7Sarepta Therapeutics Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Baseline Performance on 6MWT Correlates with Other Functional Outcomes in a Phase IIb Study of Exon-Skipping Antisense Oligonucleotide Eteplirsen for Use in Duchenne Muscular Dystrophy (DMD) (P5.091)
Jihad Saoud, Jerry Mendell, Louise Rodino-Klapac, Zarife Sahenk, Kandice Roush, Loren Bird, Linda Lowes, Lindsay Alfano, Ana Maria Gomez Ramirez, Sarah Lewis, Vinod Malik, Kim Shontz, Christopher Shilling, Peter Sazani, Edward Kaye
Neurology Apr 2014, 82 (10 Supplement) P5.091;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE: The objective of this analysis is to evaluate the correlations at Baseline between patients’ performance on the 6MWT and a variety of other functional measures. BACKGROUND: Duchenne Muscular Dystrophy is a degenerative X-linked genetic neuromuscular disorder with an incidence of 1 in 5,000 boys caused by mutations to the gene coding for the protein dystrophin. Patients’ qualifications for enrollment into clinical trials utilize several baseline functional measures before treatment initiation. DESIGN/METHODS: Twelve boys, aged 7 to 13 were randomized 1:1:1 to weekly IV infusion with 30mg/kg, 50mg/kg, or placebo/delayed treatment cohorts. Pearson correlation while controlling for patients’ age was used to evaluate the correlation between the maximum distance walked on the 6MWT administered at 2 consecutive days and the various functional outcomes (NSAA, rise time, 10-meter run time, timed 4-step test, FVC, FVC % predicted, MEP, and MIP) before treatment was initiated. RESULTS: Maximum distance walked on the 6MWT was statistically significantly correlated with rise time (r=-0.69), 10-meter run time (r=-0.65), FVC (r=-0.76), and MEP (r=-0.71). Moderate correlations were observed with NSAA (r=0.57, p≤0.07) and MIP (r=-0.54, p≤0.09). Correlations with the remaining functional measures failed to reach statistical significance with the lowest correlation observed with FVC % predicted (r=-0.25) and the timed 4-step test (r=-0.47). When the same variables were evaluated by using the Spearman rho coefficient (ranked data), both the NSAA and timed 4-step test became statistically significantly correlated with maximum distance walked. CONCLUSIONS: The high correlations evident among the various baseline measures suggest careful considerations to the patient selection criteria should be made at the time of designing study protocols. These findings suggest fewer criteria may be sufficient to qualify patients for clinical studies. Furthermore, and based on the mechanism of action of the experimental treatment, selecting a variety of uncorrelated measures for qualification may be warranted.

Disclosure: Dr. Saoud has received personal compensation for activities with Sarepta Therapeutics as an employee. Dr. Mendell has received research support from Sarepta Therapeutics Inc. Dr. Rodino-Klapac has received research support from Sarepta Therapeutics. Dr. Sahenk has received research support from Sarepta Therapeutics. Dr. Roush has received research support from AVIBiopharma. Dr. Bird has nothing to disclose. Dr. Lowes has received personal compensation for activities with GlaxoSmithKline Inc. as a consultant. Dr. Lowes has received research support from Novartis. Dr. Alfano has nothing to disclose. Dr. Gomez Ramirez has nothing to disclose. Dr. Lewis has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Shontz has nothing to disclose. Dr. Shilling has nothing to disclose. Dr. Sazani has received personal compensation for activities with Sarepta Therapeutics as an employee. Dr. Kaye has received personal compensation for activities with Sarepta Therapeutics as an employee.

Wednesday, April 30 2014, 3:00 pm-6:30 pm

  • Copyright © 2014 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 99 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise